Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Cendakimab Autoinjector vs Prefilled Syringe in Healthy Participants
NCT05337345Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2022
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cendakimab in eosinophilic esophagitis (EoE) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed concentration, Area under the concentration-time curve from time zero to time of last quantifiable concentration and 1 more. Started May 2022; status: completed.
02
Drugs
cendakimab
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT05337345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05337345.